Related Experiment Video
Updated: Jul 15, 2026
17:28
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
The return of thalidomide: can birth defects be prevented?
J M Lary1, K L Daniel, J D Erickson
1Division of Birth Defects and Pediatric Genetics, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3724, USA. jml2@cdc.gov
Drug Safety
|September 16, 1999
Summary
To prevent birth defects from thalidomide, the FDA created a strict program for prescribing and dispensing. However, global use and black market access raise concerns about preventing future thalidomide embryopathy epidemics.
Area of Science:
- Pharmacology
- Teratology
- Public Health
Background:
- Thalidomide, infamous for causing birth defects in the 1950s-60s, is now FDA-approved for erythema nodosum leprosum (ENL), a leprosy complication.
- Potential wider use for prevalent diseases or off-label indications necessitates measures to prevent fetal exposure.
- Previous thalidomide use led to a global epidemic of severe birth defects, highlighting the teratogenic risks.
Purpose of the Study:
- To evaluate the effectiveness of a comprehensive FDA-mandated program designed to prevent fetal exposure to thalidomide.
- To address concerns regarding the potential for a resurgence of thalidomide embryopathy with increased drug usage globally.
- To emphasize the need for non-teratogenic thalidomide analogs for treating conditions like ENL.
Main Methods:
- The FDA mandated a comprehensive program requiring registration of prescribers, pharmacies, and patients.
- Program includes mandatory contraception, periodic pregnancy testing for women of childbearing potential, and prescriber counseling on risks and safe use.
- A thalidomide registry monitors prescription, dispensing, and use, investigating all reported fetal exposures.
Main Results:
- The program's success hinges on strict compliance from patients, prescribers, and pharmacists.
- Concerns remain about widespread use in countries lacking stringent controls, as evidenced by reported cases in Brazil.
- Potential for black market access further complicates control efforts, risking increased birth defect occurrences.
Conclusions:
- The FDA's program is a critical step but requires universal adherence to prevent thalidomide embryopathy.
- Global disparities in regulatory controls and the potential for illicit drug access pose significant risks.
- Development of non-teratogenic thalidomide analogs is essential for safe and effective treatment of various conditions.
Related Concept Videos
01:52Regression Toward the Mean
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:18Functions of Thyroid Hormones
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...